Sahlgrenska Cardiomyopathy Project

NCT03527342 | Enrolling By Invitation

• 1 other identifier: SUCARD
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

This is a joint project by Sahlgrenska University Hospital: Sahlgrenska, Östra and Mölndal. Our objective is to diagnose and map patients with well phenotyped cardiomyopathies (CMP) including in depth clinical and molecular phenotyping to enable earlier and specific treatment. The project will serve as:

1. 1.resource for diagnostic and therapeutic trials
2. 2.common biomaterial bank
3. 3.resource for detailed molecular analyses on patients' biomaterials and patient specific symptoms and examination results

Conditions

Dilated Cardiomyopathies; Hypertrophic Cardiomyopathy; Restrictive Cardiomyopathy; Arrhythmogenic Right Ventricular Cardiomyopathy; Myocarditis; Sarcoidosis With Myocarditis; Giant Cell Myocarditis; Amyloidosis; Heart (Manifestation)

Outcome Measures

Primary Outcomes (1)

• Time to disease progression

  2018-2028

Other Outcomes (4)

• Progression in biomarker NT-proBNP

  2018-2028

• Changes over time in presence of autoantibodies

  2018-2028

• Disease activity evaluated by positron-emissions-tomography computed tomography (PET-CT)

  2018-2028

Study Arms (8)

Dilated Cardiomyopathy

Myocarditis

Sarcoidosis Heart

Giant Cell Myocarditis

Amyloidosis Heart

Hypertrophic Cardiomyopathies

Left Ventricular Myocardial Noncompaction Cardiomyopathy

Arrhythmogenic Right Ventricular Cardiomyopathies

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Eligible patients are all patients referred to Sahlgrenska University Hospital, Gothenburg, Sweden with a cardiomyopathy diagnose.

You may qualify if:

• Patients with primary cardiomyopathies including hereditary and inflammatory dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, left ventricular non-compaction cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, myocarditis, giant cell myocarditis, sarcoidosis and amyloidosis engaging the heart

You may not qualify if:

• Patient with other preexisting cardiac diseases such as significant valvular, ischemic or pericardial disease before they receive a cardiomyopathy diagnose
• patients \< 18 years

Sponsors & Collaborators

• Göteborg University: lead
• Sahlgrenska University Hospital: collaborator

Study Sites (1)

Göteborg University, Sahlgrenska Universitetssjukhuset

Gothenburg, Sweden

Location

MeSH Terms

Conditions

Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Cardiomyopathy, Restrictive; Arrhythmogenic Right Ventricular Dysplasia; Myocarditis; Amyloidosis

Condition Hierarchy (Ancestors)

Cardiomegaly; Heart Diseases; Cardiovascular Diseases; Cardiomyopathies; Laminopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Aortic Valve Disease; Heart Valve Diseases; Heart Defects, Congenital; Cardiovascular Abnormalities; Congenital Abnormalities; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 23, 2018
• First Posted: May 17, 2018
• Study Start: June 1, 2018
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2029
• Last Updated: November 6, 2018

Record last verified: 2018-11

Data Sharing

• IPD Sharing: Will not share

Locations

SE (1)